Sirt3 is essential for apelin-induced angiogenesis in post-myocardial infarction of diabetes

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 1, 2015, Pages 53-61

  Hou, Xuwei ^a   Zeng, Heng ^a   He, Xiaochen ^a   Chen, Jian Xiong ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apelin; Apoptosis; Diabetes; Myocardial infarction; Sirtuin 3

Indexed keywords

ADENOVIRIDAE; MUS;

ADIPOCYTOKINE; ANGIOGENIC FACTOR; APLN PROTEIN, MOUSE; SIGNAL PEPTIDE; SIRT3 PROTEIN, MOUSE; SIRTUIN 3;

ADENOVIRIDAE; ANGIOGENESIS; ANIMAL; APOPTOSIS; CELL PROLIFERATION; COMPLICATION; DEFICIENCY; ECHOGRAPHY; ENDOTHELIUM CELL; EXPERIMENTAL DIABETES MELLITUS; GENE THERAPY; GENETICS; HEART FUNCTION TEST; HEART MUSCLE; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY;

ADENOVIRIDAE; ADIPOKINES; ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIAL CELLS; GENETIC THERAPY; HEART FUNCTION TESTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; SIRTUIN 3;

EID: 84921536410     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12453     Document Type: Article

References (37)

1. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101: 2981-8.
2. Helisch A, Ware JA. Therapeutic angiogenesis for ischemic heart disease. Adv Exp Med Biol. 2000; 476: 327-50.
3. Ahn A, Frishman WH, Gutwein A, et al. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part I. Cardiol Rev. 2008; 16: 163-71.
4. Ahn A, Frishman WH, Gutwein A, et al. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-Part II. Cardiol Rev. 2008; 16: 219-29.
5. Arcidiacono MV, Traveset A, Rubinat E, et al. Microangiopathy of large artery wall: a neglected complication of diabetes mellitus. Atherosclerosis. 2013; 228: 142-7.
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287: 2570-81.
7. Buyken AE, von Eckardstein A, Schulte H, et al. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil. 2007; 14: 230-6.
8. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004; 21: 238-45.
9. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-34.
10. Chen JX, Stinnett A. Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes. 2008; 57: 3335-43.
11. Chen JX, Stinnett A. Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arterioscler Thromb Vasc Biol. 2008; 28: 1606-13.
12. Zeng H, Li L, Chen JX. Overexpression of angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS ONE. 2012; 7: e35905.
13. Tuo QH, Zeng H, Stinnett A, et al. Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol. 2008; 294: H2547-57.
14. Cox CM, D'Agostino SL, Miller MK, et al. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol. 2006; 296: 177-89.
15. Kunduzova O, Alet N, Delesque-Touchard N, et al. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J. 2008; 22: 4146-53.
16. Visser YP, Walther FJ, Laghmani el H, et al. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med. 2010; 182: 1239-50.
17. Wang W, McKinnie SM, Patel VB, et al. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc. 2013; 2: e000249.
18. Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2012; 303: H605-18.
19. Li L, Zeng H, Hou X, et al. Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction. PLoS ONE. 2013; 8: e71041.
20. Shi T, Wang F, Stieren E, et al. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005; 280: 13560-7.
21. Giralt A, Villarroya F. SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging. Biochem J. 2012; 444: 1-10.
22. Sundaresan NR, Vasudevan P, Zhong L, et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. 2012; 18: 1643-50.
23. Sack MN. The role of SIRT3 in mitochondrial homeostasis and cardiac adaptation to hypertrophy and aging. J Mol Cell Cardiol. 2012; 52: 520-5.
24. Zhao T, Li J, Chen AF. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab. 2010; 299: E110-6.
25. Sundaresan NR, Samant SA, Pillai VB, et al. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol. 2008; 28: 6384-401.
26. Sundaresan NR, Gupta M, Kim G, et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009; 119: 2758-71.
27. Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007; 21: 2644-58.
28. Chen J, Michan S, Juan AM, et al. Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy. Angiogenesis. 2013; 16: 985-92.
29. Kasai A, Shintani N, Oda M, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun. 2004; 325: 395-400.
30. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood. 2010; 115: 3166-74.
31. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221-8.
32. Qin G, Ii M, Silver M, et al. Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med. 2006; 203: 153-63.
33. Hou XW, Son J, Wang Y, et al. Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther. 2006; 20: 85-91.
34. Penn MS, Pastore J, Miller T, et al. SDF-1 in myocardial repair. Gene Ther. 2012; 19: 583-7.
35. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002; 3: 687-94.
36. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003; 107: 1322-8.
37. Liehn EA, Tuchscheerer N, Kanzler I, et al. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol. 2011; 58: 2415-23.